Provided is a series of new poly-fluorosubstituted pyrazolopyrimidine compounds or salts. The compounds are Bruton's tyrosine kinase (BTK) inhibitors. The compounds have better kinase inhibition selectivity and pharmokinetic properties. Also provided is a preparation method for the compounds. Also provided is a combination therapy including the compounds in combination with another targeted drug composition or another drug. The optimised combination therapy has a cooperative effect, inhibits the existence of a tumour better than a single targeted drug, and causes certain tumours to completely disappear. The optimised combination therapy treats drug resistance and cancer recurrence of a tumour better than a single targeted drug, and the treatment cycle is shorter. The present invention also relates to a combined compound and a pharmaceutical preparation wherein said combined compound acts as an active ingredient, said pharmaceutical preparation being safer at a lower dosage and having a cooperative effect efficacy. Also provided is a method of using the compounds and a preparation thereof to treat and inhibit an autoimmune disease or illness, a heterogeneous autoimmune disease or illness, an inflammatory disease, a cancer or an illness.La présente invention concerne une série de nouveaux composés ou sels de pyrazolopyrimidine polyfluorés. Les composés sont des inhibiteurs de la tyrosine kinase de Bruton (BTK). Les composés ont une meilleure sélectivité d'inhibition des kinases et de meilleures propriétés pharmacocinétiques. L'invention concerne également une méthode de préparation des composés. L'invention concerne également une polythérapie comprenant les composés en association avec une autre composition de médicament ciblée ou un autre médicament. La polythérapie optimisée a un effet de coopération, inhibe mieux l'existence d'une tumeur qu'un seul médicament ciblé, et amène certaines tumeurs à disparaître complètement. La polythérapie optimisée traite mieux la rés
